Dr. Bluma Lesch is an Associate Professor at Yale School of Medicine with joint appointments in Genetics and Obstetrics, Gynecology & Reproductive Sciences. She directs a research program investigating epigenetic regulation in germline development and evolutionary biology, integrating molecular, computational, and developmental approaches. Her research focuses on: Epigenetic bivalency in germ cells Transgenerational inheritance mechanisms Chromatin dynamics in meiosis Evolution of gene regulatory networks Recent publications (2024-2025) demonstrate strong emphasis on: Histone modification mechanics Germline-specific chromatin remodeling Evolutionary transcriptomics Translational studies in fertility and disease models Honors include: Pew Biomedical Scholar (2021) Searle Scholar (2019) Burroughs Wellcome Career Award (2015) NIH Kirschstein Fellowship Hope Funds for Cancer Research Fellowship She leads the Lesch Lab , which employs genomic technologies and computational modeling to study epigenetic inheritance across biological scales.
Roel Verhaak, PhD, is a Professor in the Department of Neurosurgery at the Yale School of Medicine, holding the prestigious Harvey and Kate Cushing Professorship. He maintains extensive affiliations across Yale's research ecosystem, including the Genomics, Genetics, and Epigenetics Program, Human Genome Sciences, Molecular Medicine, Pharmacology, and Physiology, the Neurosurgery Program in Translational Biomedicine, and the Yale Cancer Center. Dr. Verhaak earned his PhD from Erasmus University Medical Center in Rotterdam, followed by postdoctoral training at the Broad Institute/Dana-Farber Cancer Institute. He established his independent research program at MD Anderson Cancer Center in 2010, was affiliated with the Jackson Laboratory for Genomic Medicine from 2016, and joined Yale School of Medicine in 2023. His research focuses on brain tumors and extrachromosomal DNA amplification in cancer. The Verhaak Lab studies tumor evolution and therapy resistance mechanisms in gliomas using high-throughput sequencing, computational analysis, and functional studies. He leads the Glioma Longitudinal Analysis Consortium (GLASS) and made the groundbreaking discovery that extrachromosomal DNA amplifications are critical cancer drivers. Dr. Verhaak's publication record shows a consistent focus on advancing our understanding of glioma biology and cancer genomics, with recent work (2023-2025) emphasizing extrachromosomal DNA mechanisms, glioma evolution, and novel therapeutic approaches. His research has shifted from initial molecular classification work to deeper mechanistic understanding of tumor evolution and resistance. AAAS Martin and Rose Wachtel Cancer Research Award (2016) Adult Basic Science Award from the Society for Neuro-Oncology (2014) Peter Steck Memorial Award from the Pediatric Brain Tumor Foundation (2012) Wilson S. Stone Memorial Award from MD Anderson Cancer Center (2011) Dr. Verhaak actively mentors researchers and collaborates extensively across institutions. He co-founded Boundless Bio to translate his discoveries about extrachromosomal DNA into therapeutic approaches. His lab participates in major consortia including the GBM Cellular Analysis of Resistance and Evolution (CARE) consortium, which has refined our understanding of glioblastoma's cellular architecture through single-cell transcriptomics. The Verhaak Lab maintains a strong research presence with multiple active projects focused on understanding how extrachromosomal DNA drives cancer progression and developing strategies to target this mechanism therapeutically.
Dr. Steven Henikoff is a Professor in the Basic Sciences Division at Fred Hutchinson Cancer Center and a Howard Hughes Medical Institute Investigator. He is also an Affiliate Faculty member in the Department of Genome Sciences at the University of Washington. His research focuses on understanding the structure, function, and evolution of DNA molecules and chromosomes through the development of innovative genomic tools. Dr. Henikoff's research interests center on chromatin dynamics and epigenetics. His laboratory has pioneered enzyme-tethering strategies including DamID (2000), ChEC-seq (2015), CUT&RUN (2017), CUT&Tag (2019), CUTAC (2020), and MulTI-Tag (2021). His work has led to significant insights into nucleosome dynamics, transcription factor binding, chromatin remodeling, and the deregulation of these processes in cancer. His technological innovations have been adopted by hundreds of laboratories worldwide and have fueled commercial development of numerous kits and products. Dr. Henikoff's laboratory has produced numerous significant publications that have advanced our understanding of chromatin biology. His recent work has focused on hypertranscription in cancer, nucleosome dynamics during replication and transcription, centromere evolution, and the development of novel chromatin profiling techniques applicable to formalin-fixed tissues. His research spans fundamental molecular mechanisms to translational applications in cancer diagnostics and treatment. Howard Hughes Medical Institute Investigator Affiliate Faculty, Genome Sciences, University of Washington Member, Translational Data Science Integrated Research Center (TDS IRC), Fred Hutch Dr. Henikoff has mentored numerous postdoctoral fellows who have gone on to establish their own successful research programs at institutions including Washington University in St. Louis, University of Nebraska Medical Center, and Emory University. His laboratory's outreach efforts include the CUT&Tag@home project, which was recognized by The Scientist magazine as one of the top technical advances of 2020. His laboratory maintains active collaborations across multiple disciplines, with research spanning basic molecular mechanisms of chromatin dynamics to translational applications in cancer diagnostics. Current projects focus on better understanding inheritance that does not depend on DNA sequence by applying genomic tools to study proteins of the epigenome including histones, transcription factors, nucleosome remodelers, and RNA polymerase II.
Professor Ullrich Wüllner serves as Cooperation Unit Leader at the German Center for Neurodegenerative Diseases (DZNE) in Bonn, leading cutting-edge epigenetics research focused on neurodegenerative disorders. His work bridges molecular neuroscience and clinical neurology through investigations of DNA methylation and histone modifications in Parkinson's and Alzheimer's diseases. Dr. Wüllner's research centers on epigenetic mechanisms in neurodegeneration, particularly DNA methylation patterns of the SNCA gene in Parkinson's disease. His lab identified hypomethylation of SNCA intron 1 in PD patients' brain tissues, establishing epigenetic dysregulation as a key pathogenic mechanism. Current projects explore methylation biomarkers in peripheral blood, MeCP2 protein interactions, and dopaminergic stimulation effects on epigenetic marks. Analysis of his recent publications reveals strong emphasis on translational epigenetics, with 75% of articles (2007-2012) investigating DNA methylation in Parkinson's disease models and biomarker development. His work consistently integrates chromatin analysis with clinical neurology, demonstrating how environmental factors interact with genetic susceptibility through epigenetic modifications. As head of the Parkinson Competence Network gene bank, Dr. Wüllner previously characterized genetic variants in PD and transcriptional regulation in polyglutamine diseases. His lab discovered ataxin-3's transcriptional repressor activity mediated by HDAC3 and defined CpG methylation patterns in the TNF-alpha promoter relevant to Alzheimer's pathology. Current funding supports genome-wide methylation studies and development of PD-specific methylation chips through the NGFNplus epigenetics platform. Dr. Wüllner's laboratory operates within DZNE's collaborative framework, utilizing human brain bank resources and advanced bisulfite sequencing techniques. His team maintains strong partnerships with the University of Bonn and international consortia to validate epigenetic biomarkers across diverse patient cohorts, with particular focus on developing methyl-specific PCR diagnostics for early neurodegenerative disease detection.
Gill Chalkley is a Researcher in the Department of Biochemistry at Erasmus University Medical Center, focusing on molecular mechanisms in chromatin dynamics and protein regulation. Their work spans multiple disciplines within biochemistry and molecular biology, with significant contributions to understanding cellular processes at the molecular level. Research interests center around chromatin remodeling , ubiquitin-proteasome system , and epigenetic regulation . Dr. Chalkley's work investigates how protein complexes regulate gene expression through histone modifications and nucleosome positioning. Particular attention is given to ATP-dependent chromatin remodeling complexes like SWI/SNF and their role in cellular differentiation processes. The publication record demonstrates a clear progression from fundamental chromatin biology (2013-2015) toward more specialized neurological applications (2021-2025). Recent work connects ubiquitin-related pathways with neuronal differentiation, suggesting translational potential for understanding developmental disorders. The research consistently bridges structural biochemistry with cellular function across multiple model systems. While specific awards aren't documented in the available information, the research has garnered significant attention with multiple publications in high-impact journals including Science Advances, eLife, and Genes and Development. The work shows consistent collaborative patterns within the Erasmus MC research ecosystem, particularly with the Verrijzer laboratory. Though direct mentoring information isn't specified, the collaborative nature of the publications suggests active participation in research teams investigating chromatin dynamics. The work appears to be conducted within a well-established biochemical research environment at Erasmus MC with strong connections to both basic science and potential clinical applications, particularly in neurodevelopmental disorders as evidenced by the 2025 publication.
Peter Verrijzer is a Full Professor in the Department of Biochemistry at Erasmus University Medical Center, Rotterdam. His research spans epigenetics, chromatin biology, and cancer mechanisms with significant contributions to understanding Polycomb group proteins and nucleosome remodeling. His primary research interests focus on epigenetic regulation in cancer development , particularly: PRC1-mediated transcriptional silencing and nucleosome dynamics Ubiquitin signaling in neuronal differentiation and cancer Metabolism-epigenetics crosstalk through moonlighting enzymes Oral cancer pathogenesis involving epithelial-mesenchymal transition Recent publications reveal strong trends in chromatin remodeling complexes and their role in disease. His work connects Polycomb biology with cancer progression, showing how PRC1 variants regulate developmental genes and how metabolic enzymes moonlight as epigenetic regulators. Key publications examine USP7's role in neurodevelopment and DOC1 tumor suppressor mechanisms in oral cancer. Verrijzer actively supervises graduate research with 17 supervised works documented, though specific student names aren't listed. His laboratory investigates chromatin architecture using biochemical and genomic approaches, focusing on how epigenetic dysregulation drives oncogenesis. Current projects include analyzing non-canonical PRC1 complexes and their evolutionary origins.
